PNPierre-Emmanuel Noly

Pierre-Emmanuel Noly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pierre-Emmanuel Noly has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Michel Carrier

    Department of Surgery, Montreal Heart Institute, Université de Montreal, Montreal, QC, Canada

    2 shared publications
  • Yoan Lamarche

    Department of Surgery, Montreal Heart Institute, Université de Montreal, Montreal, QC, Canada

    2 shared publications
  • Abas Dani

    Department of Cardiac Surgery, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada

    1 shared publication
  • Anelechi C. Anyanwu

    Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, NY

    1 shared publication
  • Anique Ducharme

    Department of Surgery, Montreal Heart Institute, Université de Montreal, Montreal, QC, Canada

    1 shared publication
  • Claudius Mahr

    Division of Cardiology, Department of Medicine, University of Washington, Seattle, Wash

    1 shared publication

Latest Publications

  • Open Access

    Cardiac Transplantation in a Patient With Situs Inversus Totalis and Extracardiac Fontan

    by Abas Dani, Ismail Bouhout, Nancy Poirier, Pierre-Emmanuel Noly


  • Open Access

    What Are SAVR Indications in the TAVI Era?

    by William Davalan, Walid Ben Ali, Sebastián Mrad, Pierre-Emmanuel Noly

    While surgical aortic valve replacement (SAVR) has traditionally been regarded as the gold standard for severe symptomatic aortic stenosis (AS), transcatheter aortic valve implantation (TAVI) has emerged as a compelling less invasive alternative for patients with severe AS across the entire surgical risk spectrum. Despite TAVI’s increasing utilization and promising outcomes, SAVR continues to be an essential treatment modality for certain patient populations, including individuals with complex aortic anatomies unsuitable for TAVI, patients presenting with significant aortic regurgitation, individuals requiring concomitant surgical procedures, and cases involving infective endocarditis. Furthermore, concerns regarding the long-term durability and complication profile of transcatheter valves underscore the importance of individualized patient assessment, especially for younger patients requiring optimal lifetime management strategies. This review examines the evolving role of SAVR amidst the growing adoption of TAVI and highlights key considerations for selecting the most appropriate treatment strategy for patients with aortic valve disease, incorporating insights from recent advancements in transcatheter technologies and the latest clinical trial evidence.


  • Assessment of Ex Vivo Murine Biventricular Function in a Langendorff Model

    by Pierre-Emmanuel Noly, Suyash Naik, Paul Tang, Ienglam Lei

    Primary graft dysfunction (PGD) remains the leading cause of early death following heart transplantation. Prolonged ischemic time during cold preservation is an important risk factor for PGD, and reliable evaluation of cardiac function is essential to study the functional responses of the donor heart after cold preservation. The accompanying video describes a technique to assess murine right and left ventricular function using ex vivo perfusion based in a Langendorff model after cold preservation for different durations. In brief, the heart is isolated and stored in a cold histidine-tryptophan-ketoglutarate (HTK) solution. Then, the heart is perfused with a Kreb buffer in a Langendorff model for 60 min. A silicone balloon is inserted into the left and right ventricle, and cardiac functional parameters are recorded (dP/dt, pressure-volume relationships). This protocol allows the reliable evaluation of cardiac function after different heart preservation protocols. Importantly, this technique allows the study of cardiac preservation responses specifically in native cardiac cells. The use of very small murine hearts allows access to an enormous array of transgenic mice to investigate the mechanisms of PGD.


  • Open Access

    Key questions about aortic insufficiency in patients with durable left ventricular assist devices

    by Eliza Calin, Anique Ducharme, Michel Carrier, Yoan Lamarche, Walid Ben Ali, Pierre-Emmanuel Noly

    The development of the latest generation of durable left ventricular assist devices (LVAD) drastically decreased adverse events such as pump thrombosis or disabling strokes. However, time-related complications such as aortic insufficiency (AI) continue to impair outcomes following durable LVAD implantation, especially in the context of long-term therapy. Up to one-quarter of patients with durable LVAD develop moderate or severe AI at 1 year and its incidence increases with the duration of support. The continuous regurgitant flow within the left ventricle can compromise left ventricular unloading, increase filling pressures, decrease forward flow and can thus lead to organ hypoperfusion and heart failure. This review aims to give an overview of the epidemiology, pathophysiology, and clinical consequences of AI in patients with durable LVAD.


  • A bridge-to-bridge approach to heart transplantation using extracorporeal membrane oxygenation and total artificial heart

    by Pierre-Emmanuel Noly, Jaime Moriguchi, Keyur B. Shah, Anelechi C. Anyanwu, Claudius Mahr, Eric Skipper, Mariève Cossette, Yoan Lamarche, Michel Carrier